Search Results

There are 4918 results for: content related to: Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease

  1. You have free access to this content
    Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease

    Journal of Neurochemistry

    Volume 114, Issue 2, July 2010, Pages: 499–511, Christopher Kobylecki, M. Angela Cenci, Alan R. Crossman and Paula Ravenscroft

    Article first published online : 28 APR 2010, DOI: 10.1111/j.1471-4159.2010.06776.x

  2. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Article first published online : 19 JUN 2012, DOI: 10.1002/mds.25051

  3. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure

    Movement Disorders

    Volume 21, Issue 10, October 2006, Pages: 1578–1594, Susan H. Fox, Anthony E. Lang and Jonathan M. Brotchie

    Article first published online : 27 JUL 2006, DOI: 10.1002/mds.20936

  4. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

    Movement Disorders

    Volume 21, Issue 11, November 2006, Pages: 1879–1891, Naomi P. Visanji, Jordi Gomez-Ramirez, Tom H. Johnston, Donna Pires, Valerie Voon, Jonathan M. Brotchie and Susan H. Fox

    Article first published online : 7 SEP 2006, DOI: 10.1002/mds.21073

  5. The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease

    Movement Disorders

    Volume 26, Issue 7, June 2011, Pages: 1225–1233, James B. Koprich, Susan H. Fox, Tom H. Johnston, Allan Goodman, Bertrand Le Bourdonnec, Roland E. Dolle, Robert N. DeHaven, Diane L. DeHaven-Hudkins, Patrick J. Little and Jonathan M. Brotchie

    Article first published online : 4 APR 2011, DOI: 10.1002/mds.23631

  6. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 30, Issue S1, June 2015, Pages: S1–S567,

    Article first published online : 12 JUN 2015, DOI: 10.1002/mds.26295

  7. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Article first published online : 28 MAY 2008, DOI: 10.1002/mds.22133

  8. Histamine H3 receptor agonists reduce L-dopa–induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

    Movement Disorders

    Volume 21, Issue 6, 6 June 2006, Pages: 839–846, Jordi Gomez-Ramirez, Tom H. Johnston, Naomi P. Visanji, Susan H. Fox and Jonathan M. Brotchie

    Article first published online : 10 MAR 2006, DOI: 10.1002/mds.20828

  9. The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates

    Movement Disorders

    Volume 25, Issue 13, 15 October 2010, Pages: 2084–2093, Tom H. Johnston, Susan H. Fox, Matthew J. Piggott, Juha-Matti Savola and Jonathan M. Brotchie

    Article first published online : 7 SEP 2010, DOI: 10.1002/mds.23172

  10. Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease

    Parkinson's Disease: Non-Motor and Non-Dopaminergic Features

    Susan H. Fox, Jonathan M. Brotchie, Pages: 432–454, 2011

    Published Online : 27 JUN 2011, DOI: 10.1002/9781444397970.ch38

  11. Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP-macaque model of Parkinson's disease

    Movement Disorders

    Volume 25, Issue 10, 30 July 2010, Pages: 1379–1390, Tom H. Johnston, Anne van der Meij, Jonathan M. Brotchie and Susan H. Fox

    Article first published online : 22 MAR 2010, DOI: 10.1002/mds.23069

  12. Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

    Movement Disorders

    Volume 18, Issue 8, August 2003, Pages: 872–883, Juha-Matti Savola, Michael Hill, Mia Engstrom, Hannele Merivuori, Siegfried Wurster, Steven G. McGuire, Susan H. Fox, Alan R. Crossman and Jonathan M. Brotchie

    Article first published online : 6 MAY 2003, DOI: 10.1002/mds.10464

  13. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

    Movement Disorders

    Volume 29, Issue 6, May 2014, Pages: 772–779, Wai Kin D. Ko, Elsa Pioli, Qin Li, Steve McGuire, Audrey Dufour, Todd B. Sherer, Erwan Bezard and Maurizio F. Facheris

    Article first published online : 7 MAR 2014, DOI: 10.1002/mds.25859

  14. Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: Results of a pilot study

    Synapse

    Volume 69, Issue 3, March 2015, Pages: 99–102, Philippe Huot, Tom H. Johnston, Susan H. Fox and Jonathan M. Brotchie

    Article first published online : 20 JAN 2015, DOI: 10.1002/syn.21801

  15. Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease

    Movement Disorders Clinical Practice

    Emmanuelle Pourcher and Philippe Huot

    Article first published online : 25 JUL 2015, DOI: 10.1002/mdc3.12187

  16. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease

    Movement Disorders

    Volume 20, Issue 4, April 2005, Pages: 403–409, Monty A. Silverdale, S.L. Nicholson, A.R. Crossman and J.M. Brotchie

    Article first published online : 9 DEC 2004, DOI: 10.1002/mds.20345

  17. You have free access to this content
    Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

    British Journal of Pharmacology

    Volume 164, Issue 4, October 2011, Pages: 1357–1391, Susan Duty and Peter Jenner

    Article first published online : 26 SEP 2011, DOI: 10.1111/j.1476-5381.2011.01426.x

  18. Poster session 1: A. Basic science, genetics, neuropharmacology, Parkinson's Disease

    Movement Disorders

    Volume 17, Issue S5, November 2002, Pages: S17–S64,

    Article first published online : 21 OCT 2002, DOI: 10.1002/mds.10349

  19. Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application

    ELECTROPHORESIS

    Volume 31, Issue 11, June 2010, Pages: 1903–1911, Hsin-Hua Yeh, Yuan-Han Yang and Su-Hwei Chen

    Article first published online : 5 MAY 2010, DOI: 10.1002/elps.201000001

  20. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset

    Movement Disorders

    Volume 18, Issue 11, November 2003, Pages: 1301–1305, Michael P. Hill, Erwan Bezard, Steven G. McGuire, Alan R. Crossman, Jonathan M. Brotchie, Ann Michel, Renee Grimée and Henrik Klitgaard

    Article first published online : 21 AUG 2003, DOI: 10.1002/mds.10542